Nuvation Bio Inc
General ticker "NUVB" information:
- Sector: Health Care
- Industry: Pharmaceuticals
- Capitalization: $759.4M
Nuvation Bio Inc follows the US Stock Market performance with the rate: 35.4%.
Estimated limits based on current volatility of 4.2%: low 2.58$, high 2.80$
Factors to consider:
- Current price 25.7% above estimated high
- Earnings for 9 months up through Q3 are below our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2023-12-31 to 2025-12-30
- 2023-12-31 to 2024-12-30 estimated range: [0.87$, 2.12$]
- 2024-12-30 to 2025-12-30 estimated range: [1.08$, 2.44$]
Financial Metrics affecting the NUVB estimates:
- Negative: Non-GAAP EPS, $ of -0.33 <= 0.10
- Negative: Operating profit margin, % of -100 <= 1.03
- Negative: Operating cash flow per share per price, % of -18.55 <= 2.35
- Negative: negative Net income
- Negative: Industry operating cash flow per share per price (median), % of -12.63 <= 3.85
- Positive: Inventory ratio change, % of 0 <= 0
Short-term NUVB quotes
Long-term NUVB plot with estimates
Financial data
YTD | 2021-12-31 | 2022-12-31 | 2023-12-31 |
---|---|---|---|
Operating Revenue | $0.00MM | $0.00MM | $0.00MM |
Operating Expenses | $93.32MM | $119.73MM | $99.82MM |
Operating Income | $-93.32MM | $-119.73MM | $-99.82MM |
Non-Operating Income | $6.47MM | $15.54MM | $24.02MM |
R&D Expense | $69.04MM | $87.81MM | $71.29MM |
Income(Loss) | $-86.85MM | $-104.20MM | $-75.80MM |
Profit(Loss) | $-86.85MM | $-104.20MM | $-75.80MM |
Stockholders Equity | $746.00MM | $655.08MM | $605.12MM |
Assets | $776.15MM | $672.14MM | $621.48MM |
Operating Cash Flow | $-68.19MM | $-96.11MM | $-68.00MM |
Capital expenditure | $0.28MM | $0.37MM | $0.07MM |
Investing Cash Flow | $-454.67MM | $63.46MM | $8.92MM |
Financing Cash Flow | $625.53MM | $1.33MM | $0.63MM |
Earnings Per Share* | $-0.40 | $-0.41 | $-0.35 |
* EPS are Split Adjusted, recent splits may be reflected with a delay.